A Study to Evaluate the Effect of Ceralasertib on Drug X, Drug Y and Drug Z

A Phase I, Open-label, Fixed-sequence Study to Evaluate the Effect of Ceralasertib on Pharmacokinetics of Drug X, Drug Y and Drug Z in Participants With Advanced Solid Tumours

The study aims to assess the effect of ceralasertib on the pharmacokinetics (PK) of Drug X, Drug Y and Drug Z in participants with advanced solid tumours.

Study Overview

• Status: Terminated
• Conditions: Advanced Solid Tumours
• Intervention / Treatment: Drug: Ceralasertib; Drug: Drug X; Drug: Drug Y; Drug: Drug Z

Detailed Description

This is an open-label, 3-period fixed-sequence study. The study will comprise of -

• Screening Visit (Visit 1)
• Period 1 (Visit 2)
• Period 2 (Visit 3)
• Period 3 (Visit 4)
• Follow-up Visit (Visit 5)

A wash-out period of no less than 48 hours in each period.

• Study Type: Interventional
• Enrollment (Actual): 1
• Phase: Phase 1

Contacts and Locations

Study Locations

• United Kingdom
  • Manchester, United Kingdom, M20 4BX
    • Research Site

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Adult; Older Adult
• Accepts Healthy Volunteers: No

Description

Inclusion Criteria:

• Histologically or cytologically documented locally advanced or metastatic solid tumour(s) of non-small cell lung cancer, ovarian cancer, endometrial cancer, breast cancer or prostate cancer at Screening.
• Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1 with no deterioration over the 2 weeks prior to dosing.
• Ability to swallow and retain oral medication.
• Minimum life expectancy ≥ 12 weeks in the opinion of the Investigator.
• Adequate organ and marrow function during Screening.
• Body weight > 30 kg and no cancer-associated cachexia.
• Contraceptive use by participants or participant partners should be consistent with local regulations regarding the methods of contraception for those participating in clinical studies.

Exclusion Criteria:

• Diagnosis of ataxia telangiectasia (ATR).

• History of another primary malignancy except for:

  1. Malignancy treated with curative intent and with no known active disease ≥ 5 years before the first dose of the study intervention and of low potential risk for recurrence.
  2. Basal cell carcinoma of the skin.
  3. Curatively treated in situ cancer of the cervix.
  4. Ductal carcinoma in situ.
  5. Curatively treated lymphomas (without bone marrow involvement).
  6. Squamous cell carcinoma of the skin or lentigo maligna that has undergone potentially curative therapy.
  7. Adequately treated carcinoma in situ without evidence of disease.
• History of leptomeningeal carcinomatosis.
• History of myelodysplastic syndromes (MDS)/acute myeloid leukaemia (AML) or with features suggestive of MDS/AML (as determined by prior diagnostic investigation).
• Major surgical procedure (excluding placement of vascular access) or significant traumatic injury within 4 weeks of the first dose of study intervention.
• Spinal cord compression or brain metastases for at least 4 weeks prior to start of study intervention unless asymptomatic and stable.
• Persistent toxicities, with the exception of alopecia and vitiligo, caused by previous anti-cancer therapy.
• Participants with any known predisposition to bleeding.
• Refractory nausea and vomiting, chronic gastrointestinal diseases associated with diarrhoea, or previous significant bowel resection, with clinically significant sequelae that would preclude adequate absorption of ceralasertib.

• Any of the following cardiac criteria or cardiovascular diseases -

  1. Any clinically important abnormalities in rhythm, conduction, or morphology of resting ECG.
  2. Any factors that increase the risk of arrhythmic events such as heart failure, hypokalaemia, congenital long QT syndrome, family history of long QT syndrome, or unexplained sudden death under 40 years of age.
  3. Participants at risk of brain perfusion problems.
  4. Participants with relative hypotension or uncontrolled hypertension requiring clinical intervention.
  5. Hypertensive heart disease with significant left ventricular hypertrophy or clinically significant valvular heart disease.
  6. History of atrial or ventricular arrhythmia requiring treatment.
  7. Transient ischaemic attack or stroke within 6 months prior to Screening.
• Any participant with active infection requiring systemic antibiotics, antifungal or antiviral drugs.
• Participants with confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) or active infection requiring systemic antibiotics, antifungal or antiviral drugs.
• Any prior treatment with an ATR inhibitor or checkpoint kinase inhibitor.
• Any concomitant treatment of central nervous system depressants, opioids, and centrally acting anti-hypertensive agents.
• Receipt of the last dose anti-cancer therapy within 4 weeks or 5 half-lives prior to the first dose of ceralasertib, whichever is shorter.
• Concomitant use of proton pump inhibitors, histamine H2 receptor antagonists, and other anti-acid agents.
• Palliative radiotherapy with a limited field of radiation within 2 weeks.
• Receiving or intend to receive any prescription or non-prescription drugs within 7 days or 5 half-lives before first dose of study intervention.
• Use of tobacco- or nicotine-containing products within 3 months prior to check-in or history of drug or alcohol abuse.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Ceralasertib, Drug X, Drug Y and Drug Z; Participants will receive ceralasertib twice daily (BD) from Day 1 to Day 7. Participants will also receive a single dose of Drug X on Day 5 and Day 22. Similarly, a single dose of Drug Y and Drug Z on Day 7 and Day 28.	Drug: Ceralasertib; Participants will receive repeated dosing of ceralasertib from Day 1 to Day 7 until steady state.; Other Names: AZD6738; Drug: Drug X; Participants will receive a single dose of Drug X on Day 5 and Day 22.; Drug: Drug Y; Participants will receive a single dose of Drug Y on Day 7 and Day 28.; Drug: Drug Z; Participants will receive a single dose of Drug Z on Day 7 and Day 28.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Area under plasma concentration-time curve from time 0 to infinity (AUCinf)	To assess the effect of ceralasertib on the PK of Drug X, Drug Y and Drug Z.	From Day 5 to Day 30
Area under plasma concentration-time curve from time 0 to last quantifiable concentration (AUClast)	To assess the effect of ceralasertib on the PK of Drug X, Drug Y and Drug Z.	From Day 5 to Day 30
Maximum observed concentration (Cmax)	To assess the effect of ceralasertib on the PK of Drug X, Drug Y and Drug Z.	From Day 5 to Day 30
Plasma terminal elimination half-life (plasma t1/2λz)	To assess the effect of ceralasertib on the PK of Drug X, Drug Y and Drug Z.	From Day 5 to Day 30
Terminal elimination rate constante (λz)	To assess the effect of ceralasertib on the PK of Drug X, Drug Y and Drug Z.	From Day 5 to Day 30
Time to Reach Maximum Concentration Following Drug Administration (tmax)	To assess the effect of ceralasertib on the PK of Drug X, Drug Y and Drug Z.	From Day 5 to Day 30

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Number of participants with adverse events (AEs) and serious adverse events (SAEs)	To assess the safety and tolerability of ceralasertib.	From Screening to follow up visit, for up to 65 days
Trough concentrations of ceralasertib.	To assess ceralasertib steady state.	Day 4 to Day 7

Collaborators and Investigators

• Sponsor: AstraZeneca
• Collaborators: Parexel

Study record dates

Study Major Dates

• Study Start (Actual): May 21, 2025
• Primary Completion (Actual): October 15, 2025
• Study Completion (Actual): December 18, 2025

Study Registration Dates

• First Submitted: April 14, 2025
• First Submitted That Met QC Criteria: April 14, 2025
• First Posted (Actual): April 16, 2025

Study Record Updates

• Last Update Posted (Actual): January 22, 2026
• Last Update Submitted That Met QC Criteria: January 21, 2026
• Last Verified: January 1, 2026

More Information

Terms related to this study

• Keywords: Pharmacokinetics; Drug-drug interactions
• Additional Relevant MeSH Terms: ceralasertib; factor IX, factor VII, factor X, prothrombin drug combination; drug XX Z
• Other Study ID Numbers: D533BC00003; 2024-516611-24-00 (Other Identifier: EU CT Number)

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: YES
• IPD Plan Description: Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal Vivli.org. All requests will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure. Yes, indicates that AZ are accepting requests for IPD, but this does not mean all requests will be shared.
• IPD Sharing Time Frame: AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA PhRMA Data Sharing Principles. For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST /Submission/Disclosure.
• IPD Sharing Access Criteria: When a request has been approved AstraZeneca will provide access to the anonymized individual patient-level data via secure research environment Vivli.org. Signed Data Usage Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No